LAVAL, QC, Feb. 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Wednesday, February 13, 2008, Dr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive Officer, and Mr. Gary Schmid, Chief Executive Officer of the new nutraceutical business, will present Neurochem's strategy at the 2008 BIO CEO & Investor Conference to be held at the Waldorf-Astoria, in New York (NY). The presentation will take place at 11:00 A.M. EST, in the West Foyer room.
The live Web cast of Neurochem's presentation (audio and visual) can be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NRMX&item_id=17. A replay of the presentation will begin one (1) hour after the actual presentation time, and will be available until February 20, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.
Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date hereof,
may constitute forward-looking statements. Such statements, based as they
are on the current expectations of management, inherently involve numerous
risks and uncertainties, known and unknown, many of which are beyond
Neurochem Inc.'s control. Such risks include but are not limited to: the
impact of general economic conditions, general conditions in the
pharmaceutical and/or nutraceutical industry, changes in the regulatory
environment in the jurisdictions in which the Neurochem group does
business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, that actual results may
vary once the final and quality-controlled verification of data and
analyses has been completed, as well as other risks disclosed in public
filings of Neurochem Inc. Consequently, actual future results may differ
materially from the anticipated results expressed in the forward-looking
statements. The reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These statements
speak only as of the date made and Neurochem Inc. is under no obligation
and disavows any intention to update or revise such statements as a result
of any event, circumstances or otherwise, unless required by applicable
legislation or regulation. Please see the Annual Information Form of
Neurochem Inc. for further risk factors that might affect the Neurochem
group and its business.
For further information, please contact:
Lise Hebert, PhD,
Vice President, Corporate Communications
Tel: (450) 680-4572
|SOURCE NEUROCHEM INC.|
Copyright©2008 PR Newswire.
All rights reserved